AddThis

UCB seeks approval for Vimpat as stand-alone therapy in adults

Drug already has FDA approval as add-on therapy in patients aged 17 and older

ATLANTA — Drug maker UCB is seeking approval for one of its drugs as a stand-alone therapy for epilepsy.

The company said Monday that the Food and Drug Administration had accepted its regulatory approval application for Vimpat (lacosamide) for adult epilepsy patients with partial-onset seizures. The drug is already approved as an add-on therapy for partial-onset seizures in patients aged 17 and older.

"UCB has a strong heritage in epilepsy," UCB chief medical officer and EVP Iris Loew-Friedrich said. "The US filing for lacosamide in monotherapy is another step forward for people living with epilepsy."

 

© 2014 Drug Store News. All Rights Reserved.